Biotek-snakken — November 2020
-
SVB Leerink analyst Geoffrey Porges maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $122 to $119.
Copyright
Benzinga. All rights reserved. Write to [email protected] with any questions about this content. Benzinga does not provide investment advice. -
Tror, at det var i en af præsentationerne tilbage i september, at Ali meldte ud, at de ikke ville komme med flere drypvise data på zw49, med forventede at komme med dose escalation data i dec. Nu kan jeg selvf. ikke finde det igen.Tilbage i juli lovede han også flere ph.2 resultater for zw25 kombier i løbet af 6-12 måneder.
-
Til alle jer som endnu ikke er Plus-supporter: https://www.proinvestor.com/donation
-
Nye data fra Sutro: https://www.sutrobio.com/american-society-of-hematology-conference-2020-stro-001-abstract/. Desværre ikke det helt vilde at komme efter, stadig tidligt i forløbet
-
Velkommen til den nye AMBU chat https://www.proinvestor.com/index.php?p=group&groupid=126
-
Alligator Bioscience - præsenterer deres CD40 antibody (Mitazalimab) på World Immunotherapy Congress. De vil vise benchmark med konkurrende CD40 target stoffer, og mener selv de potentielt har et best-in-class CD40-stof...spændende hvad de vil vise. Andre som også er i aktien?
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind